197 related articles for article (PubMed ID: 11952541)
21. Calcium homeostasis remains unaffected after 12 weeks' therapy with calcitriol 3 microg/g ointment; no correlation with extent of psoriasis.
Barker JN; Berth-Jones J; Groves R; Omerod AD; Rizova E; Griffiths CE
J Dermatolog Treat; 2003 Jan; 14(1):14-21. PubMed ID: 12745850
[TBL] [Abstract][Full Text] [Related]
22. Current experience with tacalcitol ointment in the treatment of psoriasis.
Gollnick H; Menke T
Curr Med Res Opin; 1998; 14(4):213-8. PubMed ID: 9891193
[TBL] [Abstract][Full Text] [Related]
23. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting.
van de Kerkhof PC; van der Valk PG; Swinkels OQ; Kucharekova M; de Rie MA; de Vries HJ; Damstra R; Oranje AP; de Waard-van der Spek FB; van Neer P; Lijnen RL; Kunkeler AC; van Hees C; Haertlein NG; Hol CW
Br J Dermatol; 2006 Oct; 155(4):800-7. PubMed ID: 16965431
[TBL] [Abstract][Full Text] [Related]
24. Placebo-controlled evaluation of the irritant potential of tacalcitol (1a,24-dihydroxyvitamin D3) in healthy volunteers.
Schlotmann K; Ortland C; Neumann NJ; Ruzicka T; Lehmann P
Contact Dermatitis; 2000 May; 42(5):260-3. PubMed ID: 10789839
[TBL] [Abstract][Full Text] [Related]
25. Calcitriol ointment and clobetasol propionate cream: a new regimen for the treatment of plaque psoriasis.
Lahfa M; Mrowietz U; Koenig M; Simon JC
Eur J Dermatol; 2003; 13(3):261-5. PubMed ID: 12804986
[TBL] [Abstract][Full Text] [Related]
26. Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.
Kawaguchi M; Mitsuhashi Y; Kondo S
J Dermatol; 2003 Nov; 30(11):801-4. PubMed ID: 14684937
[TBL] [Abstract][Full Text] [Related]
27. The effects of topical calcipotriol on systemic calcium homeostasis in patients with chronic plaque psoriasis.
Bourke JF; Mumford R; Whittaker P; Iqbal SJ; Le Van LW; Trevellyan A; Hutchinson PE
J Am Acad Dermatol; 1997 Dec; 37(6):929-34. PubMed ID: 9418759
[TBL] [Abstract][Full Text] [Related]
28. Proliferation is the main epidermal target in the treatment of psoriatic plaques with once daily application of tacalcitol ointment.
Castelijns FA; Gerritsen MJ; van Vlijmen-Willems IM; van Erp PJ; van de Kerkhof PC
Acta Derm Venereol; 1999 Mar; 79(2):111-4. PubMed ID: 10228627
[TBL] [Abstract][Full Text] [Related]
29. Calcipotriol ointment versus cream in psoriasis vulgaris.
Duweb G; Aldebani S; Elzorghany A; Benghazil M; Alhaddar J
Int J Clin Pharmacol Res; 2003; 23(2-3):47-51. PubMed ID: 15018018
[TBL] [Abstract][Full Text] [Related]
30. Calcitriol ointment 3 microg/g is safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis.
Lebwohl M; Ortonne JP; Andres P; Briantais P
Cutis; 2009 Apr; 83(4):205-12. PubMed ID: 19445311
[TBL] [Abstract][Full Text] [Related]
31. Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study.
Ring J; Kowalzick L; Christophers E; Schill WB; Schöpf E; Ständer M; Wolff HH; Altmeyer P
Br J Dermatol; 2001 Mar; 144(3):495-9. PubMed ID: 11260005
[TBL] [Abstract][Full Text] [Related]
32. Profile of clinical efficacy and safety of topical tacalcitol.
Leone G; Pacifico A
Acta Biomed; 2005 Apr; 76(1):13-9. PubMed ID: 16116820
[TBL] [Abstract][Full Text] [Related]
33. Topical becocalcidiol for the treatment of psoriasis vulgaris: a randomized, placebo-controlled, double-blind, multicentre study.
Helfrich YR; Kang S; Hamilton TA; Voorhees JJ
Br J Dermatol; 2007 Aug; 157(2):369-74. PubMed ID: 17596167
[TBL] [Abstract][Full Text] [Related]
34. Long-term use of topical calcipotriol in chronic plaque psoriasis.
Ramsay CA; Berth-Jones J; Brundin G; Cunliffe WJ; Dubertret L; van de Kerkhof PC; Menne T; Wegmann E
Dermatology; 1994; 189(3):260-4. PubMed ID: 7949479
[TBL] [Abstract][Full Text] [Related]
35. High dose topical calcipotriol consistently reduces serum parathyroid hormone levels.
Bourke JF; Berth-Jones J; Mumford R; Iqbal SJ; Hutchinson PE
Clin Endocrinol (Oxf); 1994 Sep; 41(3):295-7. PubMed ID: 7955435
[TBL] [Abstract][Full Text] [Related]
36. Tacalcitol: A useful adjunct to narrow band ultraviolet B phototherapy in psoriasis.
Aggarwal P; Aggarwal K; Jain VK
J Dermatolog Treat; 2016 Nov; 27(6):546-551. PubMed ID: 27052200
[TBL] [Abstract][Full Text] [Related]
37. High-concentration (20 mug/g) tacalcitol ointment therapy on refractory psoriasis vulgaris with low response to topical corticosteroids.
Katayama I; Ohkawara A; Ohkido M; Harada S; Tamaki K; Nakagawa H; Hori Y; Nishiyama S
Eur J Dermatol; 2002; 12(6):553-7. PubMed ID: 12459526
[TBL] [Abstract][Full Text] [Related]
38. Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group.
Highton A; Quell J
J Am Acad Dermatol; 1995 Jan; 32(1):67-72. PubMed ID: 7822519
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris.
Darley CR; Cunliffe WJ; Green CM; Hutchinson PE; Klaber MR; Downes N
Br J Dermatol; 1996 Sep; 135(3):390-3. PubMed ID: 8949431
[TBL] [Abstract][Full Text] [Related]
40. Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial.
Langley RG; Gupta A; Papp K; Wexler D; Østerdal ML; Curčić D
Dermatology; 2011; 222(2):148-56. PubMed ID: 21293107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
